Cytomed Therapeutics LTD (GDTC) — 20-F Filings
All 20-F filings from Cytomed Therapeutics LTD. Browse 3 Foreign Annual Report reports with AI-powered summaries and risk analysis.
20-F Filings (3)
-
CytoMed Advances Cell Therapies, Faces Regulatory Hurdles
— Mar 31, 2026 Risk: high
CytoMed Therapeutics Ltd (GDTC) filed its 20-F for the fiscal year ended December 31, 2025, indicating its status as an emerging growth company. The company rep -
CytoMed Therapeutics Ltd Files 20-F for FY2024
— Apr 28, 2025 Risk: low
CytoMed Therapeutics Ltd filed its 20-F report for the fiscal year ending December 31, 2024. The company, previously known as CytoMed Therapeutics Pte. Ltd. unt -
CytoMed Therapeutics Ltd Files 20-F for Fiscal Year Ended December 31, 2023
— Apr 22, 2024 Risk: low
CytoMed Therapeutics Ltd (GDTC) filed a Foreign Annual Report (20-F) with the SEC on April 22, 2024. CytoMed Therapeutics Ltd filed its annual report on Form 20
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX